shortness of breath; headache; sore throat; leg cramps; tiredness; eye pain; low mood; appetite lost; this is a spontaneous report received from a contactable reporter (consumer) from the regulatory auhtority. regulatory number: gb-mhra-webcovid-202202171626168250-nkabj. other case identifier: gb-mhra-adr 26614034. a 28-year-old male patient received bnt162b2 (comirnaty), administration date 15feb2022 (lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. vaccination history included: bnt162b2 (as dose 1, single), for covid-19 immunisation and bnt162b2 (as dose 2, single), for covid-19 immunisation. the following information was reported: dyspnoea (medically significant) with onset feb2022, outcome "recovering", described as "shortness of breath"; headache (medically significant) with onset feb2022, outcome "recovering", described as "headache"; oropharyngeal pain (medically significant) with onset feb2022, outcome "recovering", described as "sore throat"; muscle spasms (medically significant) with onset feb2022, outcome "recovered" (feb2022), described as "leg cramps"; fatigue (medically significant) with onset feb2022, outcome "recovering", described as "tiredness"; eye pain (medically significant) with onset feb2022, outcome "recovered" (feb2022), described as "eye pain"; depressed mood (medically significant) with onset feb2022, outcome "recovering", described as "low mood"; and decreased appetite (medically significant) with onset feb2022, outcome "recovering", described as "appetite lost." clinical course: patient has not had symptoms associated with covid-19 and has not had a covid-19 test. he is not enrolled in a clinical trial. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected